Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03337334
Other study ID # S57869
Secondary ID
Status Completed
Phase N/A
First received November 1, 2017
Last updated November 8, 2017
Start date June 2016
Est. completion date April 2017

Study information

Verified date November 2017
Source Katholieke Universiteit Leuven
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transcranial alternating current stimulation (tACS) is a noninvasive neuromodulation method that works by passing alternating electric current between electrodes where at least one of them is attached to the head. While tACS applied over the motor cortex at the general applied amplitude (1 mA) and using patch electrodes has been shown to entrain physiological tremor in healthy volunteers, the aim of this study is to test the feasibility of using high-amplitude tACS and to assess the effect of different electrode montages and stimulation sites in entraining physiological tremor. First, 10 subjects (arm 1) will be stimulated with 2 mA current amplitude applied between saline soaked patch square electrodes and comparison will be done between motor cortex stimulation and peripheral cortex stimulation. Then, 10 subjects (arm 2) will be stimulated using focused 4x1 montage with gel-filled cup-electrodes and 5 mA amplitude and comparison will be made between motor cortex and occipital cortex stimulation. Three outcome measurements will be measured during the experiments which are: tremor entrainment, phosphene intensity and phosphene threshold.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date April 2017
Est. primary completion date April 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Above 18

- signed informed written consent

Exclusion Criteria:

- Pregnancy

- History of Epilepsy

- Family history of Epilepsy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
tACS at tremor frequency
tACS applied between the stimulation electrodes at tremor frequency

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Katholieke Universiteit Leuven

Outcome

Type Measure Description Time frame Safety issue
Primary Tremor-stimulation phase entrainment phase locking value was calculated between the tremor signal measured using accelerometer and the stimulation signal During the 36 minutes of all sessions (3 sessions each of is 12 minutes)
Secondary Phosphene rating The subject is asked to rate the phosphene intensity during the stimulation using a visual analog scale from 0 to 10. Zero means no phosphene is perceived and the number starts to increase as the phosphene perception intensity increases to reach 10 if the subject observe only a white view Measured up to 5 minutes before the start of the stimulation sessions and lasts for 10 seconds of stimulation after which the subject gives the rating
Secondary Phosphene threshold Stimulation amplitude at which the subject starts to perceive phosphene. Stimulation starts with 0 mA amplitude and then increased gradually until phosphene is perceived (or reaching maximum amplitude). Measured 3 minutes before the start of the stimulation sessions and lasts up to 2 minutes. Stimulation at each amplitude lasts for 10 sec.
See also
  Status Clinical Trial Phase
Completed NCT02334683 - Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia N/A
Completed NCT02087046 - Deep Brain Stimulation (DBS) for the Suppression of Tremor N/A
Recruiting NCT02585583 - Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study N/A
Completed NCT04065022 - The Trans-cutaneous Effects on Physiological Tremor Entertainment During tACS N/A
Recruiting NCT04815382 - Effects of a Dynamic Upper Limb Orthosis in Patients With Parkinson's Disease N/A
Recruiting NCT03136341 - A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Phase 4